Close Menu
  • Home
  • Markets
    • Earnings
  • Banks
    • Crypto
    • Investing
  • Business
    • Retail
  • industry
    • Finance
    • Energy
    • Real Estate
  • Politics
Facebook X (Twitter) Instagram
Facebook LinkedIn
Financial Market News
Subscribe Now
  • Home
  • Markets
    • Earnings
  • Banks
    • Crypto
    • Investing
  • Business
    • Retail
  • industry
    • Finance
    • Energy
    • Real Estate
  • Politics
Financial Market News
You are at:Home»Business»CVS to pull certain cold medicines from store shelves
Business

CVS to pull certain cold medicines from store shelves

October 20, 20232 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email
OLOGI Ad 2


Cold and flu medicine including NyQuil sit on a store shelf in Miami on Sept. 12, 2023.

Joe Raedle | Getty Images

CVS is removing some of the most common cough and cold medicines from its store shelves and will no longer sell them, a company spokesperson told CNBC on Thursday. 

The company’s decision comes a month after a panel of advisors to the Food and Drug Administration unanimously determined that the main ingredient used in many popular over-the-counter cold and allergy medications doesn’t actually work to clear up congested noses when taken orally. 

The FDA has not decided whether to ask drug manufacturers and retailers such as CVS to remove products containing oral phenylephrine — a nasal decongestant found in versions of drugs such as NyQuil, Benadryl, Sudafed and Mucinex — from the market. 

However, CVS is voluntarily removing certain cough and cold medicines that contain phenylephrine as the only active ingredient from stores. 

CVS is aware of the determination made by the FDA advisors and will follow directions from the agency to ensure that products sold at the company’s stores comply with laws and regulations, the spokesperson said. They added that CVS stores will continue to offer other oral cough and cold products to meet patient needs. 

Oral products that list phenylephrine as its only active ingredient include Sudafed PE, which is marketed by Johnson & Johnson’s consumer health spinoff Kenvue. Kenvue did not immediately respond to CNBC’s request for comment about CVS’s decision. 

The Wall Street Journal first reported on CVS’ decision Thursday.

Pulling oral phenylephrine from the market entirely could affect CVS and other retail pharmacy chains, which rake in revenue from selling over-the-counter cold and allergy pills.

Retail stores in the U.S. sold 242 million bottles of drugs containing phenylephrine last year, up 30% from 2021, according to data compiled by FDA staff. Those bottles generated $1.8 billion in sales last year, the data said.

Without oral phenylephrine, patients will also likely be forced to seek out liquid and spray versions of the drugs or entirely new medications, which were not included in the review by the FDA advisors.

Don’t miss these CNBC PRO stories:



Read More: CVS to pull certain cold medicines from store shelves

TGC Banner 1
Biotech and Pharmaceuticals Biotechnology Breaking news Business business news cold CVS CVS Health Corp Health care industry Kenvue Inc medicines Pharmaceuticals pull shelves store
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleI bought a lake house for $700K. It’s now worth $1.2M. Do I sell to avoid
Next Article Big banks cut thousands of jobs, more layoffs coming

Related Posts

Iran says talks continue while it retains control of Strait of Hormuz

April 19, 2026

Trump says U.S. struck, seized Iranian-flagged cargo ship

April 19, 2026

Why software stocks, 2026’s market dogs, have joined the rally

April 19, 2026

This Is a Hard Time to Start a Career. These Two Words Can Help.

April 19, 2026
Add A Comment
Leave A Reply Cancel Reply

Energy News

Iran says talks continue while it retains control of Strait of Hormuz

EPA appoints industry players and academics to its Science Advisory Board

Iran declares Strait of Hormuz open to shipping during Lebanon ceasefire

As energy costs rise, some states back off ambitious climate goals

Banks News

White House tells “greedy” banks to “move on” from CLARITY Act stablecoin

Why regional banking strength matters more now for your port

Trump Bank Citizenship Plan Could Hit 21.3 Million Americans Lacking Proof

Credit, banking industry spends big to fight Delaware swipe fee ban

Real Estate News

NYC Mayor Mamdani Unveils Major Tax Hike On Unoccupied Luxury Real Estate

Stafford County supervisors still weighing real-estate tax rate options

WeHo For Sale: West Hollywood’s Real Estate Market Has Shifted – Here’s

You Have Some Options for Dealing With Rising Property Taxes

© 2026 finmar.news

Type above and press Enter to search. Press Esc to cancel.